Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jessica Sias

Nurse Practitioner, Family Philippi, WV Nurse Practitioner

NPI 1679942189 CMS profile 10684563

3 Health Care Drive, Philippi, WV 26416

Open in the dashboard

General payments

$5,810

295 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jessica Sias of Philippi, WV is reported in the CMS Open Payments database as having received $5,810 across 295 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,268 112
2024 General $1,550 75
2023 General $1,209 57
2022 General $196 12
2021 General $586 39

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jessica Sias
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Jessica Sias were reported at $2,268. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Jessica Sias Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $586 $124 $35–$379 $132
2022 $196 $141 $44–$430 $149
2023 $1,209 $154 $49–$476 $160
2024 $1,550 $165 $51–$504 $164
2025 $2,268 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,793 114 payments
  2. AstraZeneca Pharmaceuticals LP $724 18 payments
  3. Novo Nordisk Inc $629 37 payments
  4. GlaxoSmithKline, LLC. $606 23 payments
  5. Shield Therapeutics Inc $305 7 payments
  6. Bayer HealthCare Pharmaceuticals Inc. $212 11 payments
  7. Merck Sharp & Dohme Corporation $166 6 payments
  8. Amgen Inc. $164 10 payments
  9. Pfizer Inc. $158 9 payments
  10. Exact Sciences Corporation $143 8 payments
  11. Other $909 52 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,790 294 payments
  2. Education $20 1 payment
Products named General payments · program years 2021–2025
  1. UBRELVY $872 27 payments
  2. Ozempic $611 36 payments
  3. RYBELSUS $579 34 payments
  4. QULIPTA $511 19 payments
  5. AIRSUPRA $474 8 payments
  6. VRAYLAR Neuroscience $412 43 payments
  7. BREZTRI $364 9 payments
  8. ACCRUFER $305 7 payments
  9. VRAYLAR Neuroscience $294 33 payments
  10. SHINGRIX $264 13 payments
  11. Other $2,912 159 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 83 drugs

Part D claims

3,126

Median for Nurse Practitioner: 389

Drug cost

$373,839

Median for Nurse Practitioner: $21,885

Branded share of claims

20.2%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 45 $65,332
Ozempic Semaglutide Brand 50 $61,425
Mounjaro Tirzepatide Brand 31 $52,953
Xifaxan Rifaximin Brand 12 $37,644
Farxiga Dapagliflozin Propanediol Brand 24 $24,003
Eliquis Apixaban Brand 28 $23,233
Linzess Linaclotide Brand 18 $22,027
Xarelto Rivaroxaban Brand 22 $18,441
Kerendia Finerenone Brand 15 $10,828
Spiriva Handihaler Tiotropium Bromide Brand 17 $10,585

The 10 drugs with the highest cost, of 83 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 58 billing codes

Paid by Medicare

$42,408

Of which drugs: $9,159

Medicare patients

190

Average age 72

Services billed

2,108

115 women, 75 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 60%
Diabetes 40%
Ischemic heart disease 31%
Depression 31%
COPD 29%
Chronic kidney disease 26%
Atrial fibrillation 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for administration into muscle, 0.5 ml dosage 90656 Office 11 11 $241
Injection, methylprednisolone sodium succinate, 5 mg J2919 Office 17 525 $116

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $191
$191 — —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $170
$170 15 —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $170
$170 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $166
$166 — —
UBRELVY
  • AbbVie, Inc. $72
$72 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

295 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in West Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record